الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 266 |  |  |
| | | from | 266 | | |
Abstract
Schistosomiasis is one of the most prevalent parasitism and remains a major cause of morbidity in the world. Hepatic fibrosis is considered the major morbid sequel of schistosomiasis. Praziquantel (PZQ) is the only recommended drug by the WHO against all Schistosoma spp. However, it exhibits low and erratic bioavailability and drug resistance. Therefore, there is an urgent need to develop new drugs or to improve the existing ones. The possibility to incorporate drugs into nanoparticles opens a new era for delivering drugs selectively to the diseased site and has emerged as an innovative and promising alternative that enhances therapeutic effectiveness and minimizes undesirable side effects of PZQ. Objective: is to investigate the effect of using nanostructured niosomes loaded with PZQ as a new strategy to improve the antiparasitic and the antifibrotic effects of the drug in Schistosoma mansoni infected mice (in vivo and in vitro studies.